# Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma

> **NCT00301795** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 52 (estimated)

## Conditions studied

- Stage III Grade 1 Follicular Lymphoma
- Stage III Grade 2 Follicular Lymphoma
- Stage III Grade 3 Follicular Lymphoma
- Stage IV Grade 1 Follicular Lymphoma
- Stage IV Grade 2 Follicular Lymphoma
- Stage IV Grade 3 Follicular Lymphoma

## Interventions

- **BIOLOGICAL:** oblimersen sodium
- **BIOLOGICAL:** rituximab
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00301795
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-03
- **Primary completion:** 2007-11
- **Final completion:** —
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2013-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00301795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00301795, "Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00301795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*